Mediators of a long-term movement abnormality in a Drosophila melanogaster model of classic galactosemia | Citedby Results | Disease Models & Mechanisms | The Company of Biologists

Skip to Main Content

Skip Nav Destination

Mediators of a long-term movement abnormality in a Drosophila melanogaster model of classic galactosemia

Dis Model Mech (2012) 5 (6): 796–803.

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

A Novel Variant of ATP5MC3 Associated with Both Dystonia and Spastic Paraplegia

Derek E. Neilson
Michael Zech
Robert B. Hufnagel
Jesse Slone
Xinjian Wang
Shelli Homan
Lisa M. Gutzwiller
Elizabeth J. Leslie
Nancy D. Leslie
Jianfeng Xiao
Peter Hedera
Mark S. LeDoux
Brian Gebelein
Friederike Wilbert
Matthias Eckenweiler
Juliane Winkelmann
Donald L. Gilbert
Taosheng Huang

Movement Disorders (2022) 37 (2): 375.

A pilot study of neonatal GALT gene replacement using AAV9 dramatically lowers galactose metabolites in blood, liver, and brain and minimizes cataracts in GALT‐null rat pups

Shauna A. Rasmussen
Jennifer M. I. Daenzer
Judith L. Fridovich‐Keil

Journal of Inherited Metabolic Disease (2021) 44 (1): 272.

Current and Future Treatments for Classic Galactosemia

Britt Delnoy
Ana I. Coelho
Maria Estela Rubio-Gozalbo

Journal of Personalized Medicine (2021) 11 (2): 75.

Pathophysiology and targets for treatment in hereditary galactosemia: A systematic review of animal and cellular models

Minela Haskovic
Ana I. Coelho
Jörgen Bierau
Jo M. Vanoevelen
Laura K. M. Steinbusch
Luc J. I. Zimmermann
Eduardo Villamor‐Martinez
Gerard T. Berry
M. Estela Rubio‐Gozalbo

Journal of Inherited Metabolic Disease (2020) 43 (3): 392.

Functional analysis of glycosylation using Drosophila melanogaster

Shoko Nishihara

Glycoconjugate Journal (2020) 37 (1): 1.

Repurposing drugs for the treatment of galactosemia

David J. Timson

Expert Opinion on Orphan Drugs (2019) 7 (10): 443.

Acute and long-term outcomes in a Drosophila melanogaster model of classic galactosemia occur independently of galactose-1-phosphate accumulation

Jennifer M. I. Daenzer
Patricia P. Jumbo-Lucioni
Marquise L. Hopson
Kerry R. Garza
Emily L. Ryan
Judith L. Fridovich-Keil

Disease Models & Mechanisms (2016)

The molecular basis of galactosemia — Past, present and future

David J. Timson

Gene (2016) 589 (2): 133.

Altered synaptic architecture and glycosylated synaptomatrix composition in aDrosophilaclassic galactosemia disease model

Patricia Jumbo-Lucioni
William Parkinson
Kendal Broadie

Disease Models & Mechanisms (2014)

The Human dsRNA binding protein PACT is unable to functionally substitute for the Drosophila dsRNA binding protein R2D2

Benjamin K Dickerman
Jocelyn A McDonald
Ganes C Sen

F1000Research (2014) 2: 220.

Manganese-Based Superoxide Dismutase Mimics Modify Both Acute and Long-Term Outcome Severity in aDrosophila melanogasterModel of Classic Galactosemia

Patricia P. Jumbo-Lucioni
Emily L. Ryan
Marquise L. Hopson
Heather M. Bishop
Tin Weitner
Artak Tovmasyan
Ivan Spasojevic
Ines Batinic-Haberle
Yongliang Liang
Dean P. Jones
Judith L. Fridovich-Keil

Antioxidants & Redox Signaling (2014) 20 (15): 2361.

GALK inhibitors for classic galactosemia

Kent Lai
Matthew B Boxer
Anna Marabotti

Future Medicinal Chemistry (2014) 6 (9): 1003.

Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia

Emily L. Ryan
Mary Ellen Lynch
Elles Taddeo
Tyler J. Gleason
Michael P. Epstein
Judith L. Fridovich‐Keil

Journal of Inherited Metabolic Disease (2013) 36 (6): 1049.

The Human dsRNA binding protein PACT is unable to functionally substitute for the Drosophila dsRNA binding protein R2D2

Benjamin K Dickerman
Jocelyn A McDonald
Ganes C Sen

F1000Research (2013) 2: 220.